One-liner#

COPD management centers on smoking cessation (the only intervention that slows decline), GOLD-based inhaler escalation (LAMA first, add LABA, then ICS if eosinophils elevated), pulmonary rehabilitation, and preventing exacerbations through vaccinations and optimized maintenance therapy.

Quick nav#

• Definition and epidemiology
• Pathophysiology
• Clinical presentation
• Diagnostic workup
• Treatment
• Patient education
• Prognosis and monitoring
• Special populations
• When to refer
• Smartphrase snippets
• Related pages

Definition and epidemiology#

Diagnostic criteria#

COPD is defined by persistent airflow limitation that is not fully reversible, confirmed by spirometry showing FEV1/FVC <0.70 post-bronchodilator.

GOLD Severity Classification (by FEV1 % predicted, post-bronchodilator):

• GOLD 1 (Mild): FEV1 ≥80%
• GOLD 2 (Moderate): FEV1 50-79%
• GOLD 3 (Severe): FEV1 30-49%
• GOLD 4 (Very Severe): FEV1 <30%

GOLD ABE Assessment (guides treatment):

• Group A: mMRC 0-1 or CAT <10, AND 0-1 moderate exacerbations (no hospitalizations)
• Group B: mMRC ≥2 or CAT ≥10, AND 0-1 moderate exacerbations (no hospitalizations)
• Group E (Exacerbator): ≥2 moderate exacerbations OR ≥1 hospitalization (regardless of symptoms)

Epidemiology#

Prevalence is approximately 16 million diagnosed adults in the US, with an estimated equal number undiagnosed. Third leading cause of death in the US. Risk factors include tobacco smoking (80-90% of cases), occupational exposures (coal, silica, cadmium), indoor air pollution (biomass fuel), alpha-1 antitrypsin deficiency (1-2% of cases), and childhood respiratory infections. More common in men historically, but prevalence in women is increasing. Average age at diagnosis is 40-50 years, but most patients are diagnosed after age 60.

Pathophysiology#

Mechanism (clinical understanding)#

COPD results from chronic inflammatory response to inhaled noxious particles (primarily tobacco smoke), leading to two overlapping processes:

Emphysema (parenchymal destruction):

• Protease-antiprotease imbalance: neutrophil elastase and other proteases destroy alveolar walls
• Loss of elastic recoil causes air trapping and hyperinflation
• Destruction of pulmonary capillary bed reduces gas exchange surface area
• Results in dyspnea, reduced DLCO, hyperinflation on imaging

Chronic bronchitis (airway disease):

• Airway inflammation and remodeling with goblet cell hyperplasia
• Mucus hypersecretion and impaired mucociliary clearance
• Small airway fibrosis and narrowing
• Results in chronic productive cough, frequent exacerbations

Systemic effects:

• Skeletal muscle dysfunction and cachexia (inflammatory cytokines)
• Cardiovascular disease (shared risk factors, systemic inflammation)
• Osteoporosis (steroids, inflammation, inactivity)
• Depression and anxiety (common comorbidities)

Why patients exacerbate:

• Viral infections (rhinovirus, influenza, RSV) — most common trigger
• Bacterial infections (H. influenzae, S. pneumoniae, M. catarrhalis, P. aeruginosa in severe COPD)
• Air pollution and environmental irritants
• Medication non-adherence
• Comorbidity decompensation (HF, PE)

How to explain to patients#

Your lungs have tiny air sacs that exchange oxygen and carbon dioxide. In COPD, these air sacs are damaged and the airways are inflamed and narrowed. This makes it hard to get air out of your lungs.

Think of it like trying to blow air through a straw that is partly blocked. The air gets trapped in your lungs, which is why you feel short of breath.

The damage is caused mainly by smoking. The most important thing you can do is quit smoking—this is the only thing that can slow down the damage. The medicines we use help open your airways and reduce inflammation, but they cannot undo the damage that has already happened.

Clinical presentation#

Characteristic symptoms#

Dyspnea:

• Progressive, initially with exertion, eventually at rest
• Often described as “increased effort to breathe,” “heaviness,” “air hunger”
• Quantify with mMRC scale (0-4) or CAT score (0-40)
• Patients often unconsciously limit activity to avoid dyspnea

Chronic cough:

• Often productive, worse in morning
• May precede dyspnea by years
• Chronic bronchitis: productive cough most days for ≥3 months/year for ≥2 consecutive years

Sputum production:

• Usually mucoid; purulent during exacerbations
• Large volumes suggest bronchiectasis overlap

Other symptoms:

• Wheezing and chest tightness
• Fatigue and reduced exercise tolerance
• Weight loss and muscle wasting (advanced disease)
• Ankle swelling (cor pulmonale)
• Morning headaches (hypercapnia)

Physical exam findings#

Early/mild disease:

• May be completely normal
• Prolonged expiratory phase
• Mild wheezing

Moderate-severe disease:

• Barrel chest (increased AP diameter from hyperinflation)
• Use of accessory muscles (sternocleidomastoid, scalenes)
• Pursed-lip breathing (creates auto-PEEP)
• Decreased breath sounds (hyperinflation)
• Wheezes and/or rhonchi
• Hyperresonance to percussion

Advanced disease/cor pulmonale:

• Cyanosis
• JVD, peripheral edema, hepatomegaly (right heart failure)
• Asterixis (CO2 retention)
• Cachexia, muscle wasting

Red flags#

Require urgent evaluation:

• Acute worsening with respiratory distress (SpO2 <88%, severe dyspnea, accessory muscle use)
• Altered mental status (hypercapnia, hypoxia)
• Hemodynamic instability
• New or worsening peripheral edema with JVD (cor pulmonale)
• Hemoptysis (rule out malignancy, PE)
• Fever with purulent sputum and significant decline (pneumonia)
• Chest pain (PE, pneumothorax, ACS)

Diagnostic workup#

Initial evaluation#

Spirometry (required for diagnosis):

• Pre- and post-bronchodilator testing
• FEV1/FVC <0.70 post-bronchodilator confirms airflow obstruction
• FEV1 % predicted determines GOLD stage
• Significant bronchodilator response (≥12% AND ≥200 mL) suggests asthma overlap but does not exclude COPD
• Repeat annually to track progression

Symptom assessment:

• mMRC Dyspnea Scale:
  • 0: Dyspnea only with strenuous exercise
  • 1: Dyspnea when hurrying or walking up slight hill
  • 2: Walks slower than peers or stops when walking at own pace
  • 3: Stops after walking ~100 meters or few minutes on level ground
  • 4: Too breathless to leave house or breathless when dressing
• CAT Score: 8-question validated questionnaire (0-40); ≥10 indicates high symptom burden

Exacerbation history:

• Number of moderate exacerbations (requiring steroids and/or antibiotics) in past year
• Number of hospitalizations for COPD in past year
• ≥2 moderate OR ≥1 hospitalization = Group E (high risk)

Basic labs:

• CBC: polycythemia (chronic hypoxia), anemia (comorbidity)
• BMP: baseline before diuretics if cor pulmonale
• Alpha-1 antitrypsin level: check once in ALL COPD patients (WHO recommendation)
  • If low (<80 mg/dL or <11 μmol/L), confirm with genotyping
  • Especially important if early-onset (<45 years), minimal smoking history, or family history

Pulse oximetry:

• At rest and with exertion (6-minute walk or walk around office)
• SpO2 ≤88% at rest or with exertion indicates need for supplemental oxygen evaluation

CXR:

• Hyperinflation (flattened diaphragms, increased retrosternal airspace)
• Bullae
• Rule out other pathology (mass, infiltrate, effusion)
• Not diagnostic but supports clinical picture

Confirmatory testing#

Full PFTs with DLCO (if available):

• Confirms obstruction pattern
• DLCO reduced in emphysema (parenchymal destruction)
• Lung volumes show hyperinflation (increased TLC, RV)
• Helps differentiate from asthma (DLCO normal in asthma)

CT chest (not routine, but indicated for):

• Suspected bronchiectasis
• Lung cancer screening eligibility (age 50-80, ≥20 pack-years, current smoker or quit within 15 years)
• Evaluation for lung volume reduction surgery or bullectomy
• Unexplained symptoms or discordance between symptoms and spirometry
• Characterizes emphysema distribution and severity

ABG:

• Not routine in stable outpatients
• Indicated if SpO2 <92%, suspected hypercapnia, or severe disease
• Chronic hypercapnia: PaCO2 >45 with compensated pH (elevated HCO3)

Echocardiogram:

• If suspected pulmonary hypertension or cor pulmonale
• Elevated RVSP, RV dilation/dysfunction

When to refer for specialist workup#

Pulmonology referral for:

• Diagnostic uncertainty (asthma vs COPD vs overlap)
• Severe disease (FEV1 <50% predicted)
• Frequent exacerbations despite optimized therapy
• Rapid FEV1 decline (>40 mL/year)
• Alpha-1 antitrypsin deficiency
• Consideration for advanced therapies (lung volume reduction, transplant)
• Oxygen qualification and titration
• Young patient (<40 years) with COPD

What NOT to order#

• CT chest routinely: CXR sufficient for most patients; CT for specific indications
• Serial spirometry more than annually: once yearly is sufficient unless clinical change
• Bronchoscopy: not indicated for typical COPD; reserve for suspected malignancy or infection
• Routine ABG in stable patients: pulse oximetry sufficient for most
• Sputum cultures in stable patients: only during exacerbations if Pseudomonas risk or treatment failure
• BNP routinely: only if HF suspected

Treatment#

Goals of therapy#

1. Reduce symptoms: improve dyspnea, exercise tolerance, quality of life
2. Reduce exacerbations: prevent acute worsening and hospitalizations
3. Slow disease progression: smoking cessation is the ONLY intervention proven to slow FEV1 decline
4. Reduce mortality: smoking cessation, oxygen (if hypoxic), lung volume reduction (selected patients)

Targets:

• mMRC <2 or CAT <10 (symptom control)
• ≤1 moderate exacerbation per year, no hospitalizations
• SpO2 ≥88% at rest and with exertion (or on supplemental O2)
• Smoking cessation achieved and maintained

Non-pharmacologic management#

Smoking cessation (MOST IMPORTANT):

• Only intervention proven to slow FEV1 decline and reduce mortality
• Offer pharmacotherapy to all patients willing to quit
• Combination therapy (varenicline + NRT) most effective
• Refer to smoking cessation program
• Address at every visit; relapse is common—keep trying

Pulmonary rehabilitation:

• Indicated for ALL symptomatic COPD patients (mMRC ≥2)
• 6-12 week program of supervised exercise training + education
• Improves exercise capacity, dyspnea, quality of life, and reduces hospitalizations
• Benefits persist 12-18 months; consider maintenance program
• Refer to pulmonary rehab program; can repeat after exacerbations

Vaccinations:

• Influenza: annually (reduces exacerbations and mortality)
• Pneumococcal: PCV20 or PCV15 followed by PPSV23 (per CDC guidelines)
• COVID-19: per current recommendations
• RSV: for adults ≥60 years (reduces respiratory illness)
• Tdap: once if not previously received

Supplemental oxygen:

• Indicated if SpO2 ≤88% at rest (or PaO2 ≤55 mmHg)
• Also indicated if SpO2 89-90% with cor pulmonale, RV failure, or polycythemia (Hct >55%)
• Ambulatory oxygen if desaturation with exertion to ≤88%
• Improves survival in hypoxemic COPD (NOTT and MRC trials)
• Requires formal oxygen qualification documentation
• Titrate to SpO2 88-92% (avoid over-oxygenation in CO2 retainers)

Other non-pharmacologic measures:

• Nutrition: address malnutrition and cachexia; high-protein diet
• Activity: encourage regular physical activity within limits
• Avoid triggers: smoke, air pollution, occupational exposures
• Anxiety/depression screening and treatment (common comorbidities)
• Advance care planning: discuss goals of care, especially in severe disease

GOLD 2024 Initial Pharmacotherapy Algorithm:

Pharmacologic management#

Long-Acting Bronchodilators (maintenance therapy):

LAMA/LABA Combinations (preferred for Group B and E):

ICS-Containing Regimens (add if eosinophils elevated or frequent exacerbations):

Consider adding ICS if:

• Blood eosinophils ≥300 cells/μL (strong indication)
• Blood eosinophils 100-300 cells/μL with ≥2 moderate exacerbations or ≥1 hospitalization
• History of asthma or asthma-COPD overlap

Avoid ICS if:

• Blood eosinophils <100 cells/μL (unlikely to benefit)
• History of pneumonia (ICS increases pneumonia risk)
• Mycobacterial infection

ICS/LABA Combinations:

Triple Therapy (LAMA + LABA + ICS):

Adjunctive Therapies:

Short-Acting Bronchodilators (rescue):

Patient counseling points#

For maintenance inhalers:

• “These medicines work best when you use them every day, even when you feel well. They prevent symptoms and flare-ups.”
• “It may take a few weeks to notice the full benefit. Don’t stop using them if you don’t feel immediate improvement.”
• “Rinse your mouth after using inhalers with steroids to prevent thrush (white patches in your mouth).”

For inhaler technique:

• Demonstrate proper technique at every visit
• MDI: shake, exhale fully, press and inhale slowly, hold breath 10 seconds
• DPI: exhale away from device, inhale quickly and deeply, hold breath 10 seconds
• Spacer improves MDI delivery; recommend for all MDI users
• “The medicine only works if it gets into your lungs. Let me watch you use your inhaler.”

For exacerbations:

• “A flare-up means your breathing suddenly gets worse. You may cough more, have more mucus, or feel more short of breath.”
• “If you have a flare-up, use your rescue inhaler more often and call us. You may need steroids or antibiotics.”
• “Know the warning signs: more shortness of breath, more cough, change in mucus color, fever.”

For oxygen:

• “Oxygen is a medicine. Use it as prescribed—usually at least 15 hours per day, including while sleeping.”
• “Oxygen helps your heart and brain work better. It can help you live longer and feel better.”
• “Never smoke or be near open flames while using oxygen.”

Monitoring and follow-up#

Stable COPD:

• Follow-up every 3-6 months
• Assess symptoms (mMRC, CAT), exacerbation history, medication adherence, inhaler technique
• Spirometry annually to track FEV1 decline
• Review smoking status at every visit
• Vaccinations: check and update annually

After exacerbation:

• Follow-up within 1-4 weeks
• Assess recovery, adjust maintenance therapy if needed
• Consider pulmonary rehab referral
• Review and reinforce action plan

Monitoring parameters:

Patient education#

What is this condition?#

COPD stands for chronic obstructive pulmonary disease. It is a lung disease that makes it hard to breathe. The airways in your lungs are damaged and narrowed, and the air sacs are destroyed.

COPD is usually caused by smoking. The damage builds up over many years. Once the damage happens, it cannot be undone. But you can slow down the damage and feel better with treatment.

There are two main types of COPD. One type causes the air sacs in your lungs to break down. The other type causes your airways to make too much mucus and become inflamed. Most people have some of both.

What you can do#

Quit smoking. This is the most important thing you can do. It is the only thing that can slow down the damage to your lungs. We can help you quit with medicines and support.

Take your inhalers every day, even when you feel well. They help keep your airways open and reduce swelling. Use your rescue inhaler when you feel short of breath.

Stay active. Walking and other exercise can help you breathe better and feel stronger. Ask about pulmonary rehab, which is like physical therapy for your lungs.

Get your flu shot every year and stay up to date on other vaccines. Infections can make your COPD much worse.

Avoid smoke, dust, fumes, and air pollution. These can irritate your lungs and cause flare-ups.

When to seek care#

Call your doctor if you are more short of breath than usual. Call if you are coughing more or your mucus changes color. Call if your rescue inhaler is not helping as much as usual.

Go to the emergency room if you have severe trouble breathing. Go if your lips or fingernails turn blue. Go if you feel confused or very drowsy. Go if you have chest pain.

Questions to ask your doctor#

How severe is my COPD? Am I using my inhalers correctly? What should I do if I have a flare-up? Should I be on oxygen? Am I up to date on my vaccines? Can I do pulmonary rehab?

Prognosis and monitoring#

Expected course#

With optimal treatment:

• Symptoms can be well-controlled in most patients
• Exacerbations can be reduced by 20-30% with appropriate therapy
• Quality of life can be maintained with pulmonary rehab and optimized medications
• Smoking cessation slows FEV1 decline to near-normal rate

Without treatment or with continued smoking:

• Progressive decline in FEV1 (average 30-60 mL/year in smokers vs 20-30 mL/year in non-smokers)
• Increasing dyspnea and functional limitation
• More frequent and severe exacerbations
• Development of cor pulmonale and respiratory failure
• Reduced life expectancy

Prognostic factors (BODE index):

• B: BMI (<21 = worse prognosis)
• O: Obstruction (FEV1 % predicted)
• D: Dyspnea (mMRC scale)
• E: Exercise capacity (6-minute walk distance)

Monitoring parameters#

Complications to watch for#

Acute exacerbations:

• Most common complication; major driver of morbidity and mortality
• Each exacerbation accelerates FEV1 decline
• Hospitalized exacerbations have 10% in-hospital mortality, 25% 1-year mortality

Cor pulmonale (right heart failure):

• From chronic hypoxia and pulmonary hypertension
• Signs: JVD, peripheral edema, hepatomegaly
• Treatment: oxygen, diuretics, treat underlying COPD

Pneumonia:

• Increased risk, especially with ICS use
• Maintain vaccinations; consider ICS withdrawal if recurrent pneumonia

Lung cancer:

• Shared risk factor (smoking); increased risk in COPD
• Annual low-dose CT screening if eligible (age 50-80, ≥20 pack-years, current or quit within 15 years)

Pneumothorax:

• Risk increased with bullous disease
• Suspect if sudden worsening dyspnea, pleuritic pain

Osteoporosis:

• From steroids, inactivity, systemic inflammation
• Screen with DEXA; treat if indicated

Depression and anxiety:

• Very common (40-60% prevalence)
• Screen regularly; treat aggressively

Special populations#

Elderly/geriatric#

Treatment considerations:

• COPD is primarily a disease of older adults; most patients are >65
• Inhaler technique may be impaired by arthritis, cognitive decline, poor coordination
• Consider nebulizers if unable to use inhalers effectively
• Soft mist inhalers (Respimat) easier than DPIs for patients with low inspiratory flow

Beers criteria considerations:

• Avoid long-acting anticholinergics (tiotropium, umeclidinium) with caution in patients with urinary retention or narrow-angle glaucoma
• Short-acting anticholinergics (ipratropium) also require caution
• Theophylline: avoid (narrow therapeutic index, drug interactions, toxicity)

Dose adjustments:

• No specific age-based dose adjustments for inhaled medications
• Roflumilast: use with caution; more GI side effects in elderly
• Systemic steroids: use shortest course possible; higher risk of hyperglycemia, osteoporosis, delirium

Goals may differ:

• Focus on symptom control and quality of life
• Discuss goals of care and advance directives, especially in severe disease
• Consider palliative care referral for refractory symptoms

Chronic kidney disease#

Medication adjustments:

Special considerations:

• Inhaled medications minimally absorbed; no renal dose adjustments needed
• Systemic steroids for exacerbations: no adjustment, but monitor glucose and fluid status
• CKD patients at higher risk for cardiovascular complications of COPD

Other populations#

Alpha-1 antitrypsin deficiency:

• Test all COPD patients once
• If deficient: pulmonology referral for augmentation therapy consideration
• Genetic counseling for family members
• Avoid smoking absolutely (accelerates lung destruction)

Asthma-COPD overlap (ACO):

• Features of both asthma and COPD
• Significant bronchodilator reversibility (>400 mL) or blood eosinophils >300
• Treat with ICS-LABA from the start (unlike pure COPD)
• Pulmonology referral recommended

Heart failure comorbidity:

• Very common overlap; shared risk factors
• Beta-blockers safe and indicated in HF with COPD; use cardioselective (bisoprolol, metoprolol succinate)
• Avoid non-selective beta-blockers (propranolol, carvedilol less ideal)
• Diuretics may help both conditions
• BNP can be elevated from cor pulmonale; interpret cautiously

Polypharmacy considerations:

• Anticholinergic burden: LAMAs add to anticholinergic load; monitor for urinary retention, constipation, confusion
• Beta-blockers: cardioselective agents safe; avoid non-selective in severe COPD
• Theophylline: avoid if possible; many drug interactions, narrow therapeutic index
• Sedatives/opioids: use cautiously; can suppress respiratory drive

When to refer#

Specialist referral criteria#

Pulmonology referral (routine, 2-4 weeks):

• New COPD diagnosis for confirmation and initial management guidance
• Moderate-severe disease (FEV1 <50% predicted)
• Frequent exacerbations (≥2/year) despite optimized therapy
• Diagnostic uncertainty (asthma vs COPD vs overlap)
• Consideration for advanced therapies (roflumilast, azithromycin prophylaxis)
• Oxygen qualification and titration
• Pulmonary rehab referral

Pulmonology referral (urgent, within 1-2 weeks):

• Rapid FEV1 decline (>40 mL/year)
• Severe disease with poor symptom control
• Recurrent hospitalizations
• Suspected alpha-1 antitrypsin deficiency
• Evaluation for lung volume reduction surgery or transplant

Other referrals:

• Cardiology: suspected cor pulmonale, pulmonary hypertension, HF comorbidity
• Palliative care: refractory symptoms, advanced disease, goals of care discussions
• Psychiatry: severe depression or anxiety not responding to primary care treatment
• Smoking cessation program: all current smokers

Urgency levels#

Smartphrase snippets#

COPD, stable on therapy: COPD GOLD [2/3/4], group [B/E], FEV1 [X]% predicted, on [LAMA/LAMA-LABA/triple therapy] with good symptom control (mMRC [X]). No exacerbations past year; vaccinations current. Continue current regimen, f/u 3-6 months.

COPD exacerbation, outpatient management: COPD exacerbation with increased dyspnea and [purulent sputum/cough], SpO2 [X]% on RA, no distress. Started prednisone 40mg x 5 days [± azithromycin for purulent sputum]; return precautions reviewed, f/u [3-5 days].

COPD, escalating therapy: COPD inadequately controlled on [current regimen] with mMRC [X] and [X] exacerbations/year. Escalating to [LAMA-LABA/triple therapy]; pulmonary rehab referral placed, f/u 4-8 weeks.

Related pages#

• Cough (Chronic) (complaint) — chronic cough differential including COPD
• Dyspnea (Chronic) (complaint) — chronic dyspnea evaluation and COPD workup
• Wheeze (complaint) — wheezing differential including COPD vs asthma
• Dyspnea (Acute) (complaint) — acute dyspnea including COPD exacerbation
• Cough (Acute) (complaint) — acute cough including COPD exacerbation
• Asthma (problem) — asthma management; differentiate from COPD
• Obstructive Sleep Apnea (problem) — overlap syndrome (COPD + OSA) requires treatment of both conditions
• Heart Failure (problem) — common comorbidity; differentiate cardiac vs pulmonary dyspnea
• Hypertension (problem) — cardiovascular risk management in COPD